Stock Research Report for Sun Pharmaceutical Industries Ltd
Stock score of Sun Pharmaceutical Industries Ltd moved up by 1 in a week on a 10 point scale (Source: Refinitiv). Get detailed report on Sun Pharmaceutical Industries Ltd by subscribing to ETPrime.
![Stock Reports Plus Stock Reports Plus](https://img.etimg.com/thumb/msid-83539106,width-462,height-284,imgsize-445470,resizemode-8,quality-100/stock-reports-plus.jpg)
Get 4000+ Stock Reports worth₹ 1,499* with ETPrimeat no extra cost for you
*As per competitive benchmarking of annual price. T&C apply
Make Investment decisions
with proprietary stock scores on earnings, fundamentals, relative valuation, risk and price momentum
Find new Trading ideas
with weekly updated scores and analysts forecasts on key data points
In-Depth analysis
of company and its peers through independent research, ratings, and market data
Sun Pharmaceutical Industries Limited is an India-based specialty generic pharmaceutical company with a presence in specialty, generics and consumer healthcare products. It is engaged in manufacturing, developing, and marketing a range of branded and generic formulations and active pharmaceutical ingredients (APIs). It produces a diverse and complementary portfolio of generic and specialty medicines targeting a wide spectrum of chronic and acute treatments. It offers a variety of dosage forms, including orals, creams, ointments, injectables, sprays, and liquids. Its global specialty portfolio spans advanced products in dermatology, ophthalmology, and onco-dermatology. Its marketed specialty portfolio includes Ilumya/ Ilumetri, Winlevi, Levulan Kerastick + BLU-U, Absorica LD, Odomzo, Cequa, Bromsite, Xelpros, and others. Its vertically integrated operations deliver medicines to physicians and consumers in over 100 countries. Its manufacturing facilities are spread across six continents.